Schizophrenia
Conditions
Interventions
Group A :transcutaneous electrical acupoint stimulation plus transcutaneous auricular vagus nerve stimulation
Sponsors
Kunming Psychiatric Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Diagnosed with schizophrenia according to DSM-5 criteria; (2) Aged 18-65 years; (3) Stable condition for at least 4 weeks prior to enrollment; (4) Received at least 4 weeks of stable-dose antipsychotic medication (excluding patients taking antidepressants) prior to enrollment, and maintained the same dose during the intervention period; (5) PANSS-FSNS (N1 emotional blunting, N2 emotional withdrawal, N3 communication difficulties, N4 passive/cold social withdrawal, N6 lack of spontaneity and fluency in conversation, G7 motor poverty, G16 active social avoidance) =24; (6) At least two of the three core negative symptom items scored =4 (N1, N4, N6); (7) Patient or family member agrees and signs the informed consent form. Note: Patients who meet all seven criteria above are eligible for inclusion in this study.
Exclusion criteria
Exclusion criteria: (1) PANSS-FSPS (P1 Delusions, P3 Hallucinatory Behavior, P5 Grandiosity, P6 Suspiciousness/Persecution, G9 Unusual Thought Content) > 19; (2) Two or more items in the PANSS-FSPS five-item scale score = 4; (3) Calgary Depression Scale for Schizophrenia (CDSS) total score > 6; (4) Alcohol or other substance dependence or addiction; (5) Concurrent depression, anxiety, obsessive-compulsive disorder, bipolar affective disorder, or other mental disorders; (6) History of epilepsy or other neurological diseases; (7) Suicidal tendencies or violent behavior; (8) Severe somatic diseases, including severe cardiovascular diseases, liver diseases, kidney diseases, or organic brain lesions; (9) Auricular deformities or other auricular disorders; (10) Antibiotic, anti-inflammatory, or hormone therapy within the past month; (11) Acute infectious or inflammatory diseases within the past 4 weeks, or concurrent chronic inflammatory diseases, autoimmune diseases, etc.; (12) Devices that may be affected by or affect TEAS/taVNS equipment, such as pacemakers, drug pumps, cochlear implants, or implanted brain stimulators; (13) Skin damage, infection, or other issues at the treatment site; (14) History of TEAS/taVNS treatment within the past 6 months; (15) Females who are pregnant, breastfeeding, planning pregnancy, or have given birth within the past 6 months. Note: Participants meeting any of the above criteria will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inflammatory cytokine; | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive and Negative Syndrome Scale – Factored Structure Negative Symptoms(PANSS-FSNS);treatment response rate;Scale for the Assessment of Negative Symptoms(SANS);Positive and Negative Syndrome Scale – Factored Structure Positive Symptoms(PANSS-FSPS);Positive and Negative Syndrome Scale (PANSS);Calgary Depression Scale for Schizophrenia(CDSS);Clinical Global Impression – Severity scale(CGI-S);Compliance Evaluation;Adverse Event;Treatment Satisfaction;Blinded Assessment; | — |
Countries
China
Contacts
Public ContactGong Yi
Kunming Psychiatric Hospital
Outcome results
None listed